BTIG analyst Justin Zelin reiterated a Buy rating and $20.00 price target on Jasper Therapeutics (NASDAQ: JSPR).The analyst comments "JSPR ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE